Welcome to our dedicated page for SAB BIOTHERAPEUTICS SEC filings (Ticker: SABSW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SAB Biotherapeutics filings document a clinical-stage biopharmaceutical issuer focused on SAB-142 and human immunoglobulin G therapies for autoimmune disease. Recent Form 8-K disclosures cover Regulation FD clinical presentations for the SAB-142 HUMAN trial, other clinical data announcements, and a manufacturing services agreement for clinical and commercial supply of SAB-142.
The company’s proxy materials describe annual meeting matters, director elections, board governance, stockholder voting procedures, and executive-compensation disclosures. Its SEC record also identifies capital-structure items including common stock and warrants exercisable for common stock, along with risk and forward-looking disclosure tied to clinical development, regulatory approval, manufacturing, and financing needs.
SAB Biotherapeutics reports a 5/12/2026 ownership disclosure by Perceptive Advisors and affiliated entities. The filing states that Perceptive Life Sciences Master Fund, Perceptive Advisors LLC and Joseph Edelman each may be deemed to beneficially own 6,431,743 shares of Common Stock, representing 8.4% of the class based on 76,464,094 shares outstanding as reported in the issuer's Form 10-Q filed on 5/12/2026.
The Master Fund directly holds 6,431,743 shares; Perceptive Advisors is the Master Fund's investment manager and Mr. Edelman is the managing member of Perceptive Advisors, each reported with shared voting and dispositive power over those shares.
SAB Biotherapeutics reports a 5/12/2026 ownership disclosure by Perceptive Advisors and affiliated entities. The filing states that Perceptive Life Sciences Master Fund, Perceptive Advisors LLC and Joseph Edelman each may be deemed to beneficially own 6,431,743 shares of Common Stock, representing 8.4% of the class based on 76,464,094 shares outstanding as reported in the issuer's Form 10-Q filed on 5/12/2026.
The Master Fund directly holds 6,431,743 shares; Perceptive Advisors is the Master Fund's investment manager and Mr. Edelman is the managing member of Perceptive Advisors, each reported with shared voting and dispositive power over those shares.
SAB Biotherapeutics disclosure: Caligan Partners LP and David Johnson report beneficial ownership of 7,967,207 shares of Common Stock, representing 10.4% of the class based on 76,464,094 shares outstanding as of May 6, 2026.
The statement says Caligan acts as investment manager for certain funds and accounts and that Mr. Johnson is the managing partner; voting and dispositive power are reported as sole for the stated shares. The filing is a Schedule 13G ownership disclosure.
SAB Biotherapeutics disclosure: Caligan Partners LP and David Johnson report beneficial ownership of 7,967,207 shares of Common Stock, representing 10.4% of the class based on 76,464,094 shares outstanding as of May 6, 2026.
The statement says Caligan acts as investment manager for certain funds and accounts and that Mr. Johnson is the managing partner; voting and dispositive power are reported as sole for the stated shares. The filing is a Schedule 13G ownership disclosure.
SAB Biotherapeutics, Inc. Schedule 13G: Balyasny Asset Management and affiliated entities report beneficial ownership of 5,089,939 shares, representing approximately 9.99% of the outstanding common stock. The 9.99% figure is based on 50,951,037 shares outstanding as of March 2, 2026.
The reported holdings arise from BAM's investment‑manager role for Atlas Diversified Master Fund, Ltd. (direct holder of 1,450,439 shares) and Atlas Private Holdings (Cayman) Ltd. (direct holder of 2,310,000 shares), plus shares issuable upon exercise of warrants noted in the filing. The warrants are subject to a Beneficial Ownership Limitation that prevents exercises that would result in ownership exceeding 9.99%.
SAB Biotherapeutics, Inc. Schedule 13G: Balyasny Asset Management and affiliated entities report beneficial ownership of 5,089,939 shares, representing approximately 9.99% of the outstanding common stock. The 9.99% figure is based on 50,951,037 shares outstanding as of March 2, 2026.
The reported holdings arise from BAM's investment‑manager role for Atlas Diversified Master Fund, Ltd. (direct holder of 1,450,439 shares) and Atlas Private Holdings (Cayman) Ltd. (direct holder of 2,310,000 shares), plus shares issuable upon exercise of warrants noted in the filing. The warrants are subject to a Beneficial Ownership Limitation that prevents exercises that would result in ownership exceeding 9.99%.
SAB Biotherapeutics, Inc. reported a larger net loss for the three months ended March 31, 2026 as it increased investment in its pipeline. Net loss was $18,868,885, compared with $5,196,773 a year earlier, driven by higher research and development expenses of $13,397,977 and general and administrative costs of $6,599,759.
The company strengthened its balance sheet with a March 2026 public offering of common stock and pre-funded warrants, generating approximately $86.4 million in net proceeds. Cash and cash equivalents were $20,519,724, with short-term investments of $86,871,857 and long-term investments of $110,235,540, bringing total assets to $248,470,498.
Operating cash outflow was $14,271,130 for the quarter. Management notes an accumulated deficit of $129,764,052 and expects to continue incurring losses but believes current resources will cover operating cash needs for at least twelve months. Common shares outstanding were 75,744,576 as of March 31, 2026.
SAB Biotherapeutics, Inc. reported a larger net loss for the three months ended March 31, 2026 as it increased investment in its pipeline. Net loss was $18,868,885, compared with $5,196,773 a year earlier, driven by higher research and development expenses of $13,397,977 and general and administrative costs of $6,599,759.
The company strengthened its balance sheet with a March 2026 public offering of common stock and pre-funded warrants, generating approximately $86.4 million in net proceeds. Cash and cash equivalents were $20,519,724, with short-term investments of $86,871,857 and long-term investments of $110,235,540, bringing total assets to $248,470,498.
Operating cash outflow was $14,271,130 for the quarter. Management notes an accumulated deficit of $129,764,052 and expects to continue incurring losses but believes current resources will cover operating cash needs for at least twelve months. Common shares outstanding were 75,744,576 as of March 31, 2026.
SAB Biotherapeutics, Inc. entered into a Master Manufacturing Services Agreement with Emergent BioSolutions Canada Inc. for clinical and commercial production of its SAB-142 product at Emergent’s Canadian facility. The agreement becomes a long-term framework once SAB-142 receives U.S. FDA approval.
After any FDA approval, the agreement runs for five years and includes a minimum aggregate spend of $36 million over that post-approval term. Emergent has the exclusive right to manufacture SAB-142 during the term, while SAB Biotherapeutics may use alternative sources only when Emergent cannot or declines to supply.
The agreement includes multiple termination rights, including for insolvency, non-payment, material breach, mutual agreement, or extended force majeure. If Emergent terminates due to SAB Biotherapeutics’ insolvency, non-payment, or material breach, SAB Biotherapeutics must pay Emergent an amount equal to the minimum annual aggregate spend for each remaining calendar year, less saved costs.
SAB Biotherapeutics, Inc. entered into a Master Manufacturing Services Agreement with Emergent BioSolutions Canada Inc. for clinical and commercial production of its SAB-142 product at Emergent’s Canadian facility. The agreement becomes a long-term framework once SAB-142 receives U.S. FDA approval.
After any FDA approval, the agreement runs for five years and includes a minimum aggregate spend of $36 million over that post-approval term. Emergent has the exclusive right to manufacture SAB-142 during the term, while SAB Biotherapeutics may use alternative sources only when Emergent cannot or declines to supply.
The agreement includes multiple termination rights, including for insolvency, non-payment, material breach, mutual agreement, or extended force majeure. If Emergent terminates due to SAB Biotherapeutics’ insolvency, non-payment, or material breach, SAB Biotherapeutics must pay Emergent an amount equal to the minimum annual aggregate spend for each remaining calendar year, less saved costs.
SAB Biotherapeutics (SABS) reports that Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander disclose shared beneficial ownership of 3,432,153 shares of Common Stock, representing 5.1% of the class. The filing is a joint Schedule 13G statement dated April 30, 2026.
The percent of the class was calculated using 66,934,576 shares outstanding as of March 17, 2026 per the issuer's prospectus supplement. The reported shares are held through entities over which the reporting persons have shared voting and dispositive power, and a Joint Filing Agreement is attached.
SAB Biotherapeutics (SABS) reports that Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander disclose shared beneficial ownership of 3,432,153 shares of Common Stock, representing 5.1% of the class. The filing is a joint Schedule 13G statement dated April 30, 2026.
The percent of the class was calculated using 66,934,576 shares outstanding as of March 17, 2026 per the issuer's prospectus supplement. The reported shares are held through entities over which the reporting persons have shared voting and dispositive power, and a Joint Filing Agreement is attached.
SAB Biotherapeutics is holding its 2026 virtual annual stockholder meeting on June 18, 2026 at 10:00 a.m. Eastern via www.virtualshareholdermeeting.com/SABS2026. Stockholders will vote on electing four Class II directors for three-year terms and ratifying EisnerAmper LLP as independent auditor for 2026.
Holders of 50,951,037 shares of common stock of record on April 20, 2026 may vote online, by phone, mail or during the virtual meeting. The board describes its governance structure, committee membership, director independence, director compensation and major stockholders, and recommends voting “FOR” all director nominees and “FOR” auditor ratification.
SAB Biotherapeutics is holding its 2026 virtual annual stockholder meeting on June 18, 2026 at 10:00 a.m. Eastern via www.virtualshareholdermeeting.com/SABS2026. Stockholders will vote on electing four Class II directors for three-year terms and ratifying EisnerAmper LLP as independent auditor for 2026.
Holders of 50,951,037 shares of common stock of record on April 20, 2026 may vote online, by phone, mail or during the virtual meeting. The board describes its governance structure, committee membership, director independence, director compensation and major stockholders, and recommends voting “FOR” all director nominees and “FOR” auditor ratification.
SAB Biotherapeutics reported new Phase 1 data for its fully human anti-thymocyte globulin candidate SAB-142 in adults with established type 1 diabetes. In the six-person cohort, four participants received SAB-142 and two received placebo.
All four treated participants preserved C-peptide, with three classified as super responders showing increases above baseline through Day 120, while the placebo patient showed a decline consistent with disease progression. Treated participants’ continuous glucose monitoring time in range improved from 73% at baseline to 85% at Day 120 without higher exogenous insulin use.
Biomarker data indicated CD4+ T conventional cell exhaustion without immunodepletion, supporting SAB-142’s intended mechanism. A registrational Phase 2b SAFEGUARD trial in newly diagnosed Stage 3 type 1 diabetes is ongoing, with topline data expected in the second half of 2027.
SAB Biotherapeutics reported new Phase 1 data for its fully human anti-thymocyte globulin candidate SAB-142 in adults with established type 1 diabetes. In the six-person cohort, four participants received SAB-142 and two received placebo.
All four treated participants preserved C-peptide, with three classified as super responders showing increases above baseline through Day 120, while the placebo patient showed a decline consistent with disease progression. Treated participants’ continuous glucose monitoring time in range improved from 73% at baseline to 85% at Day 120 without higher exogenous insulin use.
Biomarker data indicated CD4+ T conventional cell exhaustion without immunodepletion, supporting SAB-142’s intended mechanism. A registrational Phase 2b SAFEGUARD trial in newly diagnosed Stage 3 type 1 diabetes is ongoing, with topline data expected in the second half of 2027.
SAB Biotherapeutics, Inc. chief medical officer Alexandra Kropotova reported a routine tax-related share withholding. On the vesting of restricted stock units, 988 shares of common stock were withheld to satisfy tax obligations, rather than sold in the market. After this disposition, she holds 43,296 shares directly, including 8,743 unvested RSUs, each representing a right to receive one share of common stock.
SAB Biotherapeutics, Inc. chief medical officer Alexandra Kropotova reported a routine tax-related share withholding. On the vesting of restricted stock units, 988 shares of common stock were withheld to satisfy tax obligations, rather than sold in the market. After this disposition, she holds 43,296 shares directly, including 8,743 unvested RSUs, each representing a right to receive one share of common stock.
RA Capital Management and affiliates report beneficial ownership of 7,311,225 shares of SAB Biotherapeutics common stock, representing 9.9% of the class. The position includes common shares, Series B preferred stock, preferred stock warrants and pre-funded warrants, all subject to ownership limits.
On March 19, 2026, the RA Capital Healthcare Fund purchased pre-funded warrants to acquire 2,753,246 common shares at $3.8499 per warrant share, for an aggregate purchase price of $10,599,721.78 funded from its working capital. These pre-funded warrants are immediately exercisable at $0.0001 per share and do not expire, but contain a 9.99% beneficial ownership blocker.
RA Capital Management and affiliates report beneficial ownership of 7,311,225 shares of SAB Biotherapeutics common stock, representing 9.9% of the class. The position includes common shares, Series B preferred stock, preferred stock warrants and pre-funded warrants, all subject to ownership limits.
On March 19, 2026, the RA Capital Healthcare Fund purchased pre-funded warrants to acquire 2,753,246 common shares at $3.8499 per warrant share, for an aggregate purchase price of $10,599,721.78 funded from its working capital. These pre-funded warrants are immediately exercisable at $0.0001 per share and do not expire, but contain a 9.99% beneficial ownership blocker.